07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Why Tesaro went NOVA

BC Staff  Even though one marketed PARP inhibitor already has demonstrated that its mechanism works as maintenance therapy in platinum-sensitive ovarian cancer, Tesaro Inc. (NASDAQ:TSRO) soared on its positive Phase III data for niraparib (...
08:00 , Mar 7, 2016 |  BioCentury  |  Finance

Inside addition

The hammering that biotechs seeking follow-on financings have taken so far this year convinced Tesaro Inc. (NASDAQ:TSRO) that a privately negotiated deal with heavy insider participation was the best way to access capital. Rather than...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Financial News

Tesaro completes private placement

Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass.   Business: Cancer   Date completed: 2016-02-25   Type: Private placement   Raised: $155 million   Shares: 4.4 million   Price: $35.19   Shares after offering: 44.6 million   Investors:...
01:51 , Feb 26, 2016 |  BC Extra  |  Financial News

Tesaro raises $155M in private placement

Tesaro Inc. (NASDAQ:TSRO) raised $155 million through the sale of 4.4 million shares at $35.19 in a private placement. Kleiner Perkins Caufield & Byers and New Enterprise Associates each invested $50 million. New investors Australian...